Vancomycin AUC Dosing in Severe Obesity With Persistent MRSA Bacteremia
J.M. is a 58-year-old man (weight 142 kg, height 178 cm, BMI 45) admitted with MRSA bacteremia from a diabetic foot infection. Serum creatinine 1.6 mg/dL, estimated CrCl 52 mL/min by Cockcroft-Gault using actual body weight. He is receiving vancomycin 1 g IV every 12 hours started empirically. Blood cultures grew MRSA with vancomycin MIC 1.0 mg/L by broth microdilution. He is also on piperacillin-tazobactam for polymicrobial coverage. On day 3, a trough drawn before the fourth dose is 18 mg/L; a peak was not obtained. He remains febrile with persistent bacteremia on day 4.
1. Critique the current vancomycin regimen and propose a more appropriate initial dosing strategy.
Read the worked answer
The current regimen is likely underdosed for his body size. A fixed 1 g every 12 hours in a 142-kg patient provides only about 7 mg/kg per dose, far below usual loading and maintenance recommendations.
Appropriate approach for MRSA bacteremia:
- Loading dose: 25–30 mg/kg using actual body weight = approximately 3,550–4,260 mg; give a rounded dose such as 3,500–4,000 mg once.
- Maintenance: typically 15–20 mg/kg per dose (about 2,100–2,840 mg) every 12 hours, adjusted for CrCl 52 mL/min and subsequent AUC.
- Target AUC24/MIC 400–600 (assuming MIC 1.0 mg/L, target AUC24 400–600 mg·h/L).
- Use AUC-guided monitoring with two levels or a Bayesian approach rather than trough-only monitoring.
- Avoid concomitant piperacillin-tazobactam when possible because of the signal for increased acute kidney injury; if it must continue, monitor creatinine closely.
Document weight used, dose rationale, and monitoring plan.
2. How do you interpret the trough of 18 mg/L, and what monitoring would you recommend?
Read the worked answer
A single trough of 18 mg/L cannot reliably estimate AUC24. Trough-only monitoring is particularly misleading in obesity and renal impairment. However, an 18 mg/L trough before the fourth dose with q12h dosing raises concern that exposure may be above the target range, so the regimen should not simply be escalated without better data.
Recommended monitoring:
- Obtain a peak level 1–2 hours after the end of infusion and a trough before the next dose, or use a validated Bayesian AUC calculator.
- Confirm steady state and accurate infusion/documentation timing.
- Calculate AUC24 and adjust to 400–600 mg·h/L.
- Monitor serum creatinine daily, urine output, and signs of nephrotoxicity.
- Reassess after dose adjustment and with any change in renal function.
3. What should be done about persistent MRSA bacteremia on day 4?
Read the worked answer
Persistent bacteremia at day 4 requires a systematic response, not just a higher vancomycin dose:
- Source control: urgent evaluation of the diabetic foot for abscess, osteomyelitis, or undrained collection; surgical debridement may be necessary.
- Repeat blood cultures and consider echocardiography to evaluate for endocarditis, especially with persistent MRSA bacteremia.
- Infectious diseases consultation.
- Optimize vancomycin exposure to AUC 400–600 if vancomycin is continued.
- If bacteremia persists despite adequate exposure and source control, or if the MIC is rising, consider switching to daptomycin (with attention to dosing in obesity and monitoring for myopathy) or another appropriate agent.
- Do not add rifampin routinely unless there is prosthetic material.
- Reassess piperacillin-tazobactam need and nephrotoxicity risk.